Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy

Resting T cells, defined as non-activated T cells that have not yet encountered their specific antigen, are a highly desirable starting material for producing genetically modified CAR-T cells. They possess unique attributes, such as long-term persistence, self-renewal capacity, increased genomic stability, and multi-lineage potential, which contribute to enhanced antitumor responses. However, it is challenging to perform non-viral cell engineering of resting T cells, as these cells are in a non-dividing state and less amenable to gene delivery. They require higher energy settings for effective membrane penetration and successful transfection.

In this webinar, you will learn how non-viral gene delivery using the CTS Xenon Electroporation System in combination with CTS Xenon Lower Conductivity Electroporation Buffer can optimize the generation of CAR-T cells from resting T cells as part of a clinically relevant CAR-T cell therapy manufacturing workflow, ensuring their safety, scalability, and efficacy in cancer immunotherapy.

Attend this webinar to learn about:

The potential of resting T cells as a starting material in adoptive CAR-T cell immunotherapies
A non-viral gene editing workflow for resting T cells with expanded capabilities to deliver a variety of payloads
Harnessing a lower conductivity buffer that enables the use of higher energy settings for effective membrane penetration in difficult-to-transfect cell types
Achieving process flexibility characterized by improved transfection efficiency, cell viability, and desired cell phenotype

Akshaya Chandrasekaran

R&D Scientist at Thermo Fisher Scientific

Akshaya Chandrasekaran is an R&D Scientist currently working on consumables and analytics product development supporting Thermo Fisher Scientific's cell and gene therapy instrumentation portfolio. She received her PhD in Nanoscale Science from the State University of New York, University at Albany in 2017, specializing in aging and cancer research. Previously, she worked at Brigham and Women’s Hospital on novel gene editing-based non-viral delivery strategies for ovarian cancer, and at Intellia Therapeutics designing and testing non-viral templates for cell and gene therapies.